Multiplexing

seqWell Announces LongPlex Product to Address Multiplexing Challenges in Long Read Library Prep

Retrieved on: 
Monday, February 5, 2024
Biotechnology, Health, Genetics, Science, Research, Multiplexing, Whole genome sequencing, Marketing, Workflow, DNA, Abraxis BioScience, Entrepreneurship, Index, Genomics, Book

seqWell, a global provider of genomic library workflow solutions, today announced the early access availability of their new LongPlexTM 8kbp Multiplexing Kit, the company’s first product optimized to address workflow needs in long-read sequencing.

Key Points: 
  • seqWell, a global provider of genomic library workflow solutions, today announced the early access availability of their new LongPlexTM 8kbp Multiplexing Kit, the company’s first product optimized to address workflow needs in long-read sequencing.
  • LongPlex kits are designed to help researchers achieve a higher level of multiplexing with a simple enzymatic library barcoding workflow optimized for use with long read sequencers such as the PacBio Revio™ and Sequel II® systems.
  • seqWell has seen high customer demand for the LongPlex kits, which are now available in early access commercialization.
  • The early access configuration of the LongPlex kits are optimized for library workflows requiring fragments less than 10kbp, and designed to support a wide range of research applications including human long-read target capture assays, microbial genomics, and long read low-pass genotyping.

ChromaCode Announces Publication Highlighting Advancements in HDPCR NSCLC Assay Performance, Demonstrating Advantages Over Next Generation Sequencing in Enabling Timely Results, and as a Vital 'Rescue' Solution when NGS is not Viable

Retrieved on: 
Tuesday, November 14, 2023
Glioma, Cholangiocarcinoma, Diagnosis, DNA, NCCN, Gene, Neoplasm, Detection, National Comprehensive Cancer Network, Non-small-cell lung cancer, Deletion, Genomics, Patient, Lung cancer, Laboratory, Biomarker, Workflow, Thyroid, Limit, NGS, Cancer, LOD, RNA, Biopsy, Vaccine, Multiplexing, NSCLC

"We are very pleased with the results of this scientific study which demonstrates the utility of the NSCLC assay as an efficient and cost-effective frontline tool to benefit lung cancer patients.

Key Points: 
  • "We are very pleased with the results of this scientific study which demonstrates the utility of the NSCLC assay as an efficient and cost-effective frontline tool to benefit lung cancer patients.
  • In this newly published research, the NSCLC assay demonstrated remarkable sensitivity, even with minimal input material obtained from formalin-fixed paraffin-embedded (FFPE) tissue samples.
  • This technology addresses key challenges in NSCLC diagnosis and treatment by offering rapid biomarker testing with minimal input, making it an ideal choice for laboratories worldwide.
  • 78% of discordant results were resolved in favor of the HDPCR assay.

Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Retrieved on: 
Wednesday, November 8, 2023
Food, Multiple myeloma, CXCR2, Enrollment, B-cell lymphoma, Lupus, SITC, Cetuximab, Annual general meeting, Rituximab, SLE, CAR, Hyperbaric treatment schedules, GAAP, Graft-versus-host disease, Safety, Cancer, Therapy, Ono Pharmaceutical, Investment, Patient, IPSC, Society for Immunotherapy of Cancer, Chronic lymphocytic leukemia, Research, Immunotherapy, TRAC, CD16, NK, Clinical trial, Multiplexing, BCL, Acute leukemia, CRS, Cell, FDA, Trastuzumab, IND, ONO, ADR, HER2, Neoplasm, Protocol, Lupus Research Alliance, Destiny, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmacokinetics, Tumor microenvironment, BCMA, Vaccine, Pharmaceutical industry, Autoimmunity

SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today reported business highlights and financial results for the third quarter ended September 30, 2023.

Key Points: 
  • FT522 is the Company’s off-the-shelf, multiplexed-engineered natural killer (NK) cell product candidate that incorporates five synthetic controls of cell function.
  • In addition, as of September 30, 2023, cash receivables from the Company’s collaboration with ONO were $1.5 million.
  • Shares Outstanding: Common shares outstanding were 98.6 million, and preferred shares outstanding were 2.8 million, as of September 30, 2023.
  • ET to review financial and operating results for the quarter ended September 30, 2023.

Pillar Biosciences to Present New Scientific Data at Association for Molecular Pathology Annual Meeting

Retrieved on: 
Wednesday, November 8, 2023
Pillar, Laboratory, NSCLC, Liquid biopsy, AMP, IVD, Bandwidth (signal processing), Microsatellite instability, Automation, MSI, Neoplasm, Research, Microdissection, AM, Beckman Coulter, Detection, Chemistry, Test management, UMI, RUO, Methylation, NGS, Targeted molecular therapy for neuroblastoma, CRC, Health care, Partnership, HRD, Urinary cell-free DNA, Column, Pension fund, Medical imaging, Instrumentation, Multiplexing

NATICK, Mass., Nov. 8, 2023 /PRNewswire/ -- Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced the company and scientific collaborators will collectively present eleven studies and two corporate workshops at the 2023 Association for Molecular Pathology (AMP) Annual Meeting from November 14 -18, 2023 in Salt Lake City, UT (Booth #619).

Key Points: 
  • NATICK, Mass., Nov. 8, 2023 /PRNewswire/ -- Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced the company and scientific collaborators will collectively present eleven studies and two corporate workshops at the 2023 Association for Molecular Pathology (AMP) Annual Meeting from November 14 -18, 2023 in Salt Lake City, UT (Booth #619).
  • "Pillar Biosciences is committed to developing the data necessary to support the quality, accuracy and value of our leading IVD & RUO kitted products which can be used locally by laboratories to perform NGS sequencing," said Randy Pritchard, CEO of Pillar Biosciences, Inc. "We are proud to present these data in partnership with our collaborators at this year's AMP Annual Meeting as we continue to enable more laboratories globally with NGS assays that can be performed in a low-cost, high-multiplexed manner, thus enabling actionable, accessible NGS profiling results."
  • The scientific data presented at AMP will focus on Pillar Biosciences oncoReveal™ Research-Use-Only (RUO) kitted NGS products for liquid biopsy (LBx), HRD, methylation, solid tumor and automation.
  • Localized NGS-based Methylation Testing to Help Inform BioPharma Clinical Trials and Improve Patient Care in Oncology (Room 251F: 8:00-8:50 AM MDT)
    Highly Accurate and Automated NGS assays for Efficient Localized LBx and TBx Clinical Testing in Oncology (Room 251F: 9:00-9:51 AM MDT)
    Comparative Laboratory Performance Evaluation of Pillar Biosciences, ArcherDx, and ThermoFisher Sequencing Chemistries for The Targeted Characterization of CRC & NSCLC Samples (Poster Number: ST120)
    Robust Low Frequency Somatic Variant Detection in cfDNA Using a SLIMamp® Based Liquid Biopsy Assay (Poster Number: ST035)
    Detection of Microsatellite Instability (MSI) Using oncoReveal Core LBx, a Multiplexed, Single Tube, Liquid Biopsy Assay (Poster Number: ST107)
    Automation of The Pillar Biosciences oncoReveal Solid Tumor 22 gene panel (ORST22) on the Biomek NGeniuS Next Generation Library Prep System (Poster Number: ST029)
    QCPRECISE!™: An Automated Spatially Targeted Microdissection Platform Driven by AI Guided Digital Pathology Improves Extracted Solid Tumor DNA Purity Relative to Conventional Macrodissection (Poster Number: TT007)
    To UMI or Not to UMI: Obtaining Robust Low-Frequency Variant Identification for Liquid Biopsy with a SLIMamp-Based NGS Chemistry Without Molecular Barcoding (Poster Number: ST145)
    Robust Bioinformatic Method for Estimating Tumor Content in cfDNA Using Denoised Target Sequencing (Poster Number: I031)
    Pillar Biosciences oncoReveal methylQuant Panels: Accurate and Easy-to-Use Methylation NGS Assays Leveraging SLIMamp Technology (Poster Number: ST031)
    oncoReveal Fusion LBx: Single-Tube Multiplexed PCR-Based NGS assay for Detection of Multiple Gene Fusions from Cell Free RNA (Poster Number: ST041)
    Robust Detection of Copy Number Amplifications Using Pillar's oncoReveal™ Core LBx Panel with Low Input from Liquid Biopsy Samples (Poster Number: I011)
    Poster and abstract summaries of this research will be available onsite at Pillar Biosciences' booth #619.

TScan Therapeutics Presents Phase 1 Trial Design for Solid Tumor Program at the Society for Immunotherapy of Cancer 38th Annual Meeting

Retrieved on: 
Monday, November 6, 2023
TargetScan, FDA, NSCLC, Cervical cancer, MAGE-C2, Ovarian cancer, Society for Immunotherapy of Cancer, TCR, Neoplasm, Head, MAGE-A1, SITC, Immunotherapy, IND World's Fair Line, Annual general meeting, Lung cancer, Melanoma, Safety, Society, Cancer, Therapy, Patient, HLA, Medical imaging, Vaccine, Pharmaceutical industry, IND, Multiplexing

WALTHAM, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the presentation of six posters at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting.

Key Points: 
  • “Solid tumors are notoriously heterogenous, which may contribute to low response rates and limited duration of response following treatment with single-targeting TCR-T cell therapy.
  • TScan’s solid tumor program is designed to deliver multiplexed, enhanced TCR-T cell therapy to effectively address both target heterogeneity and HLA loss,” said Gavin MacBeath, Ph.D., Chief Executive Officer.
  • “TScan has initiated a screening protocol to test for target expression and the presence of HLA genes in patients’ tumors.
  • Using TargetScan, TScan has identified a novel B*07:02-restricted epitope in the cancer/testis antigen MAGE-C2 as a promising target for TCR-T therapy.

Domo Tactical Communications (DTC) and Silentium Defence Partner to Deliver a Low-SWaP, Covert Air Defense Solution

Retrieved on: 
Thursday, November 2, 2023
TAK, Silentium, Radio, Law enforcement, COFDM, Swap, Multiplexing, Partnership, Probability, DTC, Telescopic sight

The soldier-portable solution distributes critical sensor and targeting data real-time across DTC’s MESH or Coded Orthogonal Frequency Division Multiplexing (COFDM) waveforms to assess threats in contested environments.

Key Points: 
  • The soldier-portable solution distributes critical sensor and targeting data real-time across DTC’s MESH or Coded Orthogonal Frequency Division Multiplexing (COFDM) waveforms to assess threats in contested environments.
  • The systems are designed to operate either independently or as part of a meshed network in highly dynamic operating environments.
  • “This collaboration between DTC and Silentium provides our military, law enforcement, and commercial customers a low-SWaP passive air and surface radar system with no electromagnetic signature.
  • “DTC is a trusted partner that has a track record of delivering mission critical communications solutions to warfighters around the world,” said Simon Palumbo, Chief Experience, Silentium Defence.

Arista 7130 Series Leads the Way to 25G Ultra-Low Latency Networking

Retrieved on: 
Wednesday, October 11, 2023
Data Management, Technology, Telecommunications, Networks, Internet, Hardware, EOS, Cloud, Multimedia, NYSE, FEC, ASX, ANET, API, FDK, Blog, HFT, Q4, MetaWatch, Arista, Error correction code, MAC, Network, FPGA, Arista Networks, Video game, Printed circuit board, Computer data storage, Cryptocurrency, Multiplexing

Arista Networks (NYSE:ANET) today announced the next generation 7130 Series for ultra-low latency switching that accelerates 25G networking.

Key Points: 
  • Arista Networks (NYSE:ANET) today announced the next generation 7130 Series for ultra-low latency switching that accelerates 25G networking.
  • The Arista 7130 series 25G portfolio supports familiar low latency applications, and the optimised 25G optics minimise end-to-end latency,” said Nicholas Rakebrandt, Head of Networks at ASX.
  • The new additions to the 7130 Series are fully integrated with Arista EOS Ⓡ and CloudVision Ⓡ for consistency in day-to-day operations.
  • The Arista 7135 Series (FPGA switch with Layer 1) is planned for Q4 '23 orderability, and the Arista 7130B Series with 25G Ethernet speed will be orderable in Q1 ‘24.

TScan Therapeutics Announces Upcoming Presentations at the 38th Society for Immunotherapy of Cancer Annual Meeting

Retrieved on: 
Wednesday, September 27, 2023
Abstract, Neoplasm, Society, HPV16, Cancer, SITC, Immunotherapy, Blood, TCR, Patient, Annual general meeting, Society for Immunotherapy of Cancer, Therapy, Vaccine, Multiplexing

WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of six abstracts at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held from November 1-5, 2023, both in San Diego, CA and virtually.

Key Points: 
  • WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of six abstracts at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held from November 1-5, 2023, both in San Diego, CA and virtually.
  • Title: Product Characteristics and Clinical Trial Design for T-Plex, a Multiplexed, Enhanced T cell Receptor-Engineered T cell Therapy for Solid Tumors
    Title: Non-clinical development of T-Plex component TSC-200-A0201: A natural HPV16 E7-specific TCR-T cell therapy for the treatment of HPV16-positive solid tumors
    Title: Phase 1 trial of TSC-100 and TSC-101, Engineered T-Cell Therapies Targeting Minor Histocompatibility Antigens to Eliminate Residual Disease after Hematopoietic Cell Transplantation
    A copy of the presentation materials will be added to the “ Events and Presentations ” section of the Company’s Investor Relations website at ir.tscan.com once presentations have concluded.

ControlUp Appoints Industry Leader and Visionary Jed Ayres as CEO as it Builds Category Leadership in the Digital Employee Experience Market

Retrieved on: 
Monday, August 21, 2023
Internet, Data Management, Technology, Apps, Applications, Software, Partnership, Citrix Systems, CPC, Wyse, AppSense, JVP, Microsoft, Multimedia, GE Capital, Ganot, Organization, Erel Margalit, Ayres, Acquisition, TA Associates, GE Capital IT Solutions, Investment, K1, Multiplexing, Nexenta Systems, Control, Growth, Entrepreneurship, LG, DEX, IGEL, Jed, News, Azure Virtual Desktop, Management, Invicti athletae, Nutanix, EUC

ControlUp , the industry leader in Digital Employee Experience (DEX), announced today the appointment of software transformational leader and channel industry visionary, Jed Ayres, as the company’s new CEO.

Key Points: 
  • ControlUp , the industry leader in Digital Employee Experience (DEX), announced today the appointment of software transformational leader and channel industry visionary, Jed Ayres, as the company’s new CEO.
  • Most recently, Ayres served as CEO of IGEL, where he was instrumental in its acquisition by TA Associates and positioning it as a market leader.
  • As an essential element of the company’s leadership team, Ganot will continue to pioneer the transformation of the digital employee experience market category that he started more than a decade ago.
  • “From the first line of code that Asaf wrote, the growth potential of ControlUp has been clear to the entire industry,” commented Jed Ayres, CEO of ControlUp.